New drug could tame severe asthma and fungal allergy
NCT ID NCT07530770
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called benralizumab (Fasenra) in 20 adults with severe asthma and a fungal allergy called ABPA. The goal is to see if it can reduce asthma flare-ups that need steroids and improve quality of life. Participants receive the drug as a shot under the skin, and researchers track their progress over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Benralizumab (Fasenra), a drug given as a shot under the skin
What this could lead to
If it works, this could offer a new treatment option for people with severe asthma and ABPA, potentially reducing the need for steroids.
What could go wrong
This is a small, early-stage study with only 20 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••